ProQR Therapeutics Divested Its Ophthalmic Assets, Sepofarsen And Ultevursen, To Laboratoires Théa For An Initial Payment Of €8M And May Be Eligible For Up To €165M In Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
ProQR Therapeutics has sold its ophthalmic assets, Sepofarsen and Ultevursen, to Laboratoires Théa for an initial €8M with potential for up to €165M in milestone payments. This divestment could provide ProQR with immediate cash and future revenue, depending on the success of the assets.
December 08, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProQR's divestiture of Sepofarsen and Ultevursen to Laboratoires Théa for €8M plus potential milestone payments could strengthen its financial position and streamline its focus.
The initial payment of €8M provides immediate cash which is positive for ProQR's financial health. The potential for future milestone payments adds a positive outlook for long-term revenue. However, the actualization of these payments depends on the success of the assets, which introduces some uncertainty. The deal could also be seen as a strategic move to focus on other areas of the company's pipeline.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100